ACD PHARMACEUTICALS AS: årsregnskap 2022 vs 2021
Grew 111% on revenue, slipped into loss, cash halved-plus
approved 2023-06-30; registry 2023-08-01; journal 2023 630196
Summary
What changed
Comparing Årsregnskap 2022 with 2021 for ACD PHARMACEUTICALS AS. Revenue 12.71m NOK → 26.85m NOK (+111.3%). Net result +1.14m NOK → -12.27m NOK. Equity 13.03m NOK → 14.07m NOK.
On the constructive side: revenue rose; equity strengthened; owners injected capital. Pressures included: operating result weakened; fell into a net loss; cash fell.
Also worth watching: sharp cash drawdown; cogs moved. All figures are taken from the published annual accounts for ACD PHARMACEUTICALS AS.
At a glance
Scorecard
What improved
-
↑
Revenue rose
Operating income / revenue moved from 12.71m NOK to 26.85m NOK (+111.3% YoY). Calculated
-
↑
Equity strengthened
Book equity 13.03m NOK → 14.07m NOK (equity ratio 80.4% → 58.0%). Calculated
-
↑
Owners injected capital
Paid-in equity rose 300.0k NOK → 13.61m NOK (+13.31m NOK). Reported fact
What deteriorated
-
↓
Operating result weakened
Operating result +1.29m NOK → -15.96m NOK (op. margin 10.1% → -59.4%). Calculated
-
↓
Fell into a net loss
Net result flipped from 1.14m NOK profit to a loss of 12.27m NOK. Calculated
-
↓
Cash fell
Bank deposits 10.20m NOK → 1.67m NOK (-83.6% YoY). Calculated
Things to notice
-
·
Sharp cash drawdown
Cash fell by more than 60% YoY (10.20m NOK → 1.67m NOK). Check whether funds moved to group receivables, investments, or operating burn. Interpretation
-
·
COGS moved
COGS / varekostnad 46.4k NOK → 2.71m NOK (+5737.5% YoY). Calculated